Industry Symposia
Saturday, 7 September 2024
Lunch, 16:45-18:15
- LS-01 | AstraZeneca | Spadolini 3
Advancing precision medicine in oncology diagnostics: the role of quality HRD testing, ctDNA, and biomarkers in detection and treatment
001 | Nicola Fusco | Sequencing biomarker testing, guideline updates and AI integration in BC pathology
002 | Simon Patton | Upholding standards: the critical role of quality and consistency in HRD testing
003 | Gerhardt Attard | Navigating the maze: challenges and solutions in ctDNA testing
Sunday, 8 September 2024
Breakfast, 07:15-08:15
- BRS-01 | Paige | Spadolini 6
Revolutionizing pathology through immersive innovation
001 | Juan Retamero | Revolutionizing pathology through immersive innovation
Lunch, 13:00-14:30
- LS-02 | Daiichi | Spadolini 2
All you need to HER2 know
001 | Giuseppe Viale | Welcome and introduction
002 | Grazia Arpino | Treating cancer in the evolving era of HER2
003 | Roberto Salgado | Identifying the whole spectrum of HER2: lessons learned
004 | Josef Rüschoff | Beyond breast: similarities in identifying HER2 in gastric cancer and differences in lung cancer
005 | Giuseppe Viale | Panel discussion and Q&A
006 | Giuseppe Viale | Wrap-up and meeting close - LS-03 | Johnson & Johnson + Diatech Pharmacogenetics | Spadolini 3
Synergies in sight: navigating challenges of precision medicine via multidisciplinary collaboration in GU oncology
001 | Gabriella Nesi | Diagnostic challenges and precision medicine in bladder cancer
002 | Brigida Anna Maiorano | Current molecular landscape of bladder cancer: the oncologist’s perspective
003 | Gabriella Nesi | Discussion/Q&A
004 | Glen Kristiansen | Current considerations and challenges in prostate cancer testing
005 | Rossella Bruno | Molecular testing in GU oncology: pitfalls and analytical strategies
006 | Gabriella Nesi | Round table and Q&A - LS-04 | AstraZeneca | Spadolini 4
Beyond the human eye: diagnostic advances in digital and computational pathology
001 | Luiza Moore | Welcome & introduction
002 | Bethany Williams | Seeing eye to (A)I: digital pathology is part of pathology
003 | Fabio Pagni | Problem-solving digital pathology: attitudes, issues and solutions
004 | Luiza Moore | Quantitative Continuous Scoring: a new frontier in diagnostics – updates - LS-05 | MSD | Spadolini 5
Navigating precision pathology: biomarkers defining treatment, tissue and liquid biopsy synergy, and collaborative patient care
001 | Matteo Fassan | Welcome & introduction
002 | Matteo Fassan | Biomarker breakthroughs to treatment transformations: unveiling the shifting landscape in upper GI cancer
003 | Albrecht Stenzinger | Unlocking the potential of liquid biopsies: overcoming challenges in prostate cancer biomarker testing
004 | Kaikeen Shiu | Building partnerships in precision medicine: a collaborative approach between medical oncologists and pathologists for patient management
005 | Matteo Fassan | Panel discussion
006 | Matteo Fassan | Q&A and closing remarks
![](https://www.esp-congress.org/_Resources/Persistent/737c39f133872d884ac442e635c4c2aeeabcb0d7/ECP%20Newsletter%20Ad%20-%20Merck%207-25-24.png)
- LS-06 | Thermo Fisher Scientific | Spadolini 6
Precision oncology in every lab: connect next generation pathologists and researchers with NGS biomarker testing
001 | Nicola Normanno | Welcome & Introduction
002 | Nicola Normanno | Precision oncology in patient care (including discussion)
003 | Geetha Monon | Exploring genomic signatures in Malignant Lymphoma: potential advantages for rapid detection of relevant biomarkers
004 | Wolfram Jochum | Comprehensive genomic profiling (CGP) in high-grade serous carcinoma using peritoneal effusion samples
005 | Nicola Normanno | Discussion/Q&A
Precision oncology in every lab
Join us at the ECP 2024 symposium on Sept 8 at 13:00 in room Spadolini 6 for a deep dive into Precision Oncology. Experience the benefits of NGS Biomarker Testing in patient care & clinical research from leading experts. Don't miss it!
Visit oncomine.com/ecp2024 for more.
- LS-07 | Vitro.Bio | Spadolini 7
Addressing routine challenges in modern pathology
001 | Guido Sauter | Introduction
002 | Karen Villar Zarra | Tackling routine challenges: the power of automated staining
003 | Miguel Angel Idoate Gastearena | Advanced HPV detection: molecular pathology strategies for effective screening
004 | Melchor Saiz-Pardo | Pathology in the digital age: overcoming security challenges with cutting-edge solutions
005 | Guido Sauter | Discussion
Addressing Routine Challenges in Modern Pathology
Information overload and time pressure are increasing workloads in pathology labs. Efficient technologies and workflow optimization are crucial. Join our workshop where experts will share how to manage affordable tools to overcome these challenges.
Evening, 19:30-20:30
- ES-01 | Epredia | Spadolini 5
Digital transformation: journey to a digital workflow
001 | Catarina Eloy | Digitizing workflow: steps taken in the pre-analytical and analytical stages for workflow optimization, ensuring a successful digital pathology project
Monday, 9 September 2024
Breakfast, 07:15-08:15
- BRS-02 | Eli Lilly | Spadolini 6
Power hour: the importance of pathologists for the success of clinical studies
001 | Lorenzo Gerratana | Welcome and introduction
002 | Lorenzo Gerratana | Introduction into clinical study management
003 | Giancarlo Pruneri | Biomarker testing in clinical trials
004 | Albrecht Stenzinger | IVDR requirements for clinical studies
005 | Lorenzo Gerratana | Q&A and Round-table discussion
006 | Albrecht Stenzinger | Summary and close - BRS-03 | Roche | Spadolini 7
Improving the diagnosis of B Cell lymphomas in routine pathology practice: advances in clonality evaluation
001 | Teresa Marafioti & Marta Cañamero | Improving the diagnosis of B Cell lymphomas in routine pathology practice: advances in clonality evaluation
Lunch, 13:00-14:30
- LS-08 | Roche Diagnostics + Johnson & Johnson | Spadolini 2
Pathways to precision: practical strategies for optimizing diagnostic excellence
001 | Angelo Paolo Dei Tos | Introduction: testing pathway and patient leakage points
002 | Deniz Nart | Precision oncology in lung cancer: enhancing patient outcomes through NGS and biomarker driven therapies - Ege University experience
003 | Sylvie Lantuejoul | Optimizing the workflow to reduce failure rates
004 | Isabelle Vanden Bempt | RNA-Based sequencing for simultaneous detection of clinically actionable fusions and mutations in solid tumours
005 | Angelo Paolo Dei Tos | Round table and Q&A - LS-09 | AstraZeneca | Spadolini 3
Exploring the expanding applications of ctDNA and pathway mutations in breast cancer diagnostics
001 | Espen Walker | Welcome and introduction
002 | Elena Guerini Rocco | The utility of ctDNA in breast cancer
003 | Nicola Fusco | Emerging testing strategies for the optimization of patient profiling in HR+/HER2- breast cancer
004 | Espen Walker | Closing remarks - LS-10 | 3DHistech | Spadolini 4
Digital Pathology, IHC and Cytology
001 | Catarina Eloy | Postponing evolution: why are we choosing to ignore the need for a digital transformation in pathology?
002 | Felix Offner | Experiences with the implementation of digital cytology with Datexim and 3DHistech in Feldkirch, Austria
003 | Yukako Yagi | Digital IHC, digital microCT - LS-11 | gsk | Spadolini 5
Guiding clinical outcomes in gynaecological cancers with early and accurate biomarker testing, including case-based examples
001 | Gian Franco Zannoni | Introduction to biomarker testing in gynaecological cancers
002 | Josef Rüschoff | Biomarker testing in endometrial cancer: current status and key considerations
003 | Vanda Salutari | Treatment options according to molecular classification in endometrial cancer: clinical perspective and case study
004 | Gian Franco Zannoni | Panel discussion on biomarker testing in endometrial cancer
005 | Isabelle Treilleux | Biomarker testing in ovarian cancer: focus on HRD and BRCA
006 | Vanda Salutari | Impact of biomarker testing on patient outcomes in ovarian cancer: clinical perspective and case study
007 | Gian Franco Zannoni | Panel discussion on biomarker testing in ovarian cancer - LS-12 | Agilent Technologies | Spadolini 7
Changing testing in gastric cancer: a practical review
001 | Mar Iglesias | Welcome & focus
002 | Manuel Rodriguez-Justo | Case 1: The critical role of preanalytics in the context of case referrals
003 | Matteo Fassan | Case 2: Assessing case heterogeneity effectively: from number of biopsies to tumour staging
004 | Mar Iglesias | Q&A and closing remarks
Agilent Medical Affairs
Join our lunch symposium with a panel discussion of two challenging PD-L1 cases:
- Role of preanalytics in the context of case referrals
- Assessing case heterogeneity: from number of biopsies to tumor stages
PR7001-2710 | D0115931_1.00
Tuesday, 10 September 2024
Lunch, 13:00-14:30
- LS-13 | Roche | Spadolini 2
Precision diagnostics in ovarian cancer: traversing from testing to treatment
001 | Michelle Shiller & Domenica Lorusso - LS-14 | AstraZeneca | Spadolini 3
NSCLC: the evolution and expansion of testing across the care continuum
001 | Alexander Yarunin | Welcome and introduction
002 | Giuseppe Perrone | Navigating the evolving NSCLC testing landscape: guidance for the detection of driver and acquired resistance mutations
003 | Nicola Normanno | Plasma ctDNA testing in lung cancer: application across the care continuum
004 | Elena Guerini Rocco | Evaluating pathological complete response
005 | Alexander Yarunin | Closing remarks - LS-15 | Astellas | Spadolini 4
The Pathologist's loom: weaving CLDN18.2 into practice
001 | Matteo Fassan | Welcome and introductions
002 | Lorenzo Fornaro | Unravelling the gastric cancer and GEJ tapestry: clinical insights into the current treatment landscape and emerging biomarkers
003 | Philippe Taniere | Stitching the narrative: CLDN18.2 in the fabric of G/GEJ adenocarcinoma
004 | Matteo Fassan | The Pathologist’s canvas: exploring CLDN18.2 expression patterns in G/GEJ adenocarcinoma
005 | Matteo Fassan | Q&A session
006 | Matteo Fassan | Summary and close
![](https://www.esp-congress.org/_Resources/Persistent/778b178e7ebeee46e2a8e7d02e5d0e8f1140e34a/Astellas_CZOL2408%20website%20banner_1920x300px%20v5_3_Seite_3-1170x183.jpg)
- LS-16 | Illumina | Spadolini 5
Illumina's journey in precision pathology: from targeted panels to whole genome sequencing
001 | Giancarlo Pruneri | Empowering precision pathology: genomic tools
002 | Giulia Cangi | Enhancing precision: leveraging small panels for oncology testing
003 | Sergio Villatoro | Maximizing insights: comprehensive genomic profiling
004 | Greg Elgar | Charting the future of precision pathology: whole genome sequencing strategies
005 | Giancarlo Pruneri | Unveiling the potential: panel discussion on the future of precision pathology - LS-17 | Amgen | Spadolini 6
The future of pathology: liquid biopsy, novel biomarkers, and tumour-agnostic therapies
001 | Frédérique Penault-Llorca | Welcome and introduction
002 | Lukas Bubendorf | Liquid biopsy in NSCLC: a discourse on controversies and advancements
003 | Irene Esposito | The next frontier: FGFR2b and CLDN18.2 as promising biomarkers for G/GEJ cancers
004 | Albrecht Stenzinger | Unlocking the power of MTAP-homozygous deletion: a tumour-agnostic biomarker
005 | Frédérique Penault-Llorca | Panel discussion and Q&A
006 | Frédérique Penault-Llorca | Summary and close - LS-18 | Agilent Technologies | Spadolini 7
How can scalable, open digital pathology solutions advance diagnostic quality and efficiency in pathology practice?
001 | Jake Eden | Welcome & Agilent digital pathology focus
002 | Robert D. Goldin | Digitising liver pathology: from research to clinical delivery
003 | Teemu Tolonen | Multi-site, multi-AI pathology: quality, efficiency, and lead-time impact through scaled algorithm deployment
004 | Bert Van Der Vegt | Integration of computational pathology algorithms in the clinical digital pathology workflow: connecting the dots
005 | Holger Moch | Evolving role of digital pathology in anatomic and molecular pathology laboratories
006 | Douglas Clark| Panel discussion
Agilent Digital Pathology
Join us for a lunchtime seminar brought to you by Agilent and in association with digital pathology partners, Hamamatsu, Proscia, Visiopharm and PathAI.
D0119315_1.00
HotSpots
- Siemens Healthineers AG | 9 September 2024, 09:30-09:50, HotSpot stage at exhibition area
Navigating the galaxy of data: a journey through digital pathology
Dr. Svenja Lippok, Germany
SIEMENS HEALTHINEERS
Join us on a journey through the galaxy of data
Join us for our talk at ECP 2024 and discover a galaxy you've never seen before. Dr. Svenja Lippok, Head of Digital Pathology at Siemens Healthineers, will share her expertise on navigating digitalization.
- SOPHiA GENETICS | 9 September 2024, 10:00-10:20, HotSpot stage at exhibition area
Building evidence and confidence in liquid biopsy solutions
Dr. Alexander Yarunin, United Kingdom
Verena Schramm, Germany - SOPHiA GENETICS | 10 September 2024, 09:30-09:50, HotSpot stage at exhibition area
Insights with impact: empowering laboratories with robust CGP solutions
Verena Schramm, Germany - Sysmex Europe SE | 10 September 2024, 10:00-10:20, HotSpot stage at exhibition area
Liquid biopsy in breast cancer patient care
Maria De Bonis, Italy
Prof. Angelo Minucci, Italy
Meet-the-Expert
Roche (booth no. 15) will offer 6 Meet-the-Expert talks during the follwing times:
- Sunday, Sep 8, 13:10 - 13:30
PIK3CA; Leveraging emerging insights to drive personalised care
Dr. Nicola Fusco, Italy - Sunday, Sep 8, 14:00-14:20
The Roche Digital LightCycler: a real world performance evaluation in a Dutch hospital laboratory
Dr. Wouter Pattje, USA - Monday, Sep 9, 14:00-14:20
Advancing precision medicine: PathAI and Roche Collaborate for AI-powered companion diagnostics
Eric Walk, USA
Michael Rivers, USA - Monday, Sep 9, 13:10- 13:30
Seamless integration of Ibex's AI algorithms within Roche's navify® Digital Pathology
Michael Rivers, USA
Stuart Shand, The Netherlands - Monday, Sep 9, 16:40 - 17:00
Unlock the power of in-house comprehensive genomic profiling with AVENIO Tumor Tissue CGP Kit V2 and the new foundation medicine HRD signature
Robert Bulte, Switzerland
Muriel De Vos, Switzerland - Tuesday, Sep 10, 13:10 - 13:30
Gastric cancer testing landscape in 2024 and beyond
Mar Iglesias, Spain